Celgene Corp (CELG) 94.94 $CELG
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - 1 hr 31 mins ago
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...
Final Glance: Biotechnology companies
AP - 1 hr 45 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Wed Sep 03, 12:34PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Is It Time to Buy Celgene Corporation's Stock?
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 03, 10:03AM CDT
To put it lightly, Celgene 's stock has been on fire since the recession ended. Since the market bottomed in on March 9, 2009, Celgene shares have returned 376% as of Friday's close. CELG data by YCharts But can Celgene head even...
Bristol-Myers Returns Clazakizumab Rights, Alder Sinks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 10:02AM CDT
Bristol-Myers' (BMY) decision to opt out of the development process of clazakizumab caused the shares of Alder (ALDR) to plummet significantly.
Early Glance: Biotechnology companies
AP - Wed Sep 03, 9:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.
Celgene Shares Up 29.5% Since SmarTrend's Buy Recommendation (CELG)
Comtex SmarTrend(R) - Tue Sep 02, 9:22AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.93. In approximately 4 months, Celgene has returned 29.53% as of today's recent price of $95.77.
Next Resistance Level for Celgene (CELG) is $95.89
Comtex SmarTrend(R) - Tue Sep 02, 9:03AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $94.86 and have already reached the first level of resistance at $95.45. Analysts will be watching for a cross of the next upside pivot targets of $95.89 and $96.92.
Celgene (CELG) On Momo Momentum Watch Today
at The Street - Tue Sep 02, 8:47AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
VentiRx Pharmaceuticals Provides Corporate and Clinical Update
PR Newswire - Tue Sep 02, 7:00AM CDT
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced an update on corporate and clinical activities at the company including management structure, commitment for future funding, ongoing clinical trials and future clinical development efforts.
Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 5:30PM CDT
Regeneron (REGN) expects adjusted SG&A costs to rise further in the remaining quarters of 2014.
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth
PR Newswire - Fri Aug 29, 8:10AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6076-100free.
Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:50PM CDT
Bristol-Myers' (BMY) Daklinza has been cleared in the EU.
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - 1 hr 31 mins ago
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...
Final Glance: Biotechnology companies
AP - 1 hr 45 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Wed Sep 03, 12:34PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Is It Time to Buy Celgene Corporation's Stock?
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 03, 10:03AM CDT
To put it lightly, Celgene 's stock has been on fire since the recession ended. Since the market bottomed in on March 9, 2009, Celgene shares have returned 376% as of Friday's close. CELG data by YCharts But can Celgene head even...
Bristol-Myers Returns Clazakizumab Rights, Alder Sinks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 10:02AM CDT
Bristol-Myers' (BMY) decision to opt out of the development process of clazakizumab caused the shares of Alder (ALDR) to plummet significantly.
Early Glance: Biotechnology companies
AP - Wed Sep 03, 9:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.
Celgene Shares Up 29.5% Since SmarTrend's Buy Recommendation (CELG)
Comtex SmarTrend(R) - Tue Sep 02, 9:22AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.93. In approximately 4 months, Celgene has returned 29.53% as of today's recent price of $95.77.
Next Resistance Level for Celgene (CELG) is $95.89
Comtex SmarTrend(R) - Tue Sep 02, 9:03AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $94.86 and have already reached the first level of resistance at $95.45. Analysts will be watching for a cross of the next upside pivot targets of $95.89 and $96.92.
Celgene (CELG) On Momo Momentum Watch Today
at The Street - Tue Sep 02, 8:47AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
VentiRx Pharmaceuticals Provides Corporate and Clinical Update
PR Newswire - Tue Sep 02, 7:00AM CDT
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced an update on corporate and clinical activities at the company including management structure, commitment for future funding, ongoing clinical trials and future clinical development efforts.
Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 5:30PM CDT
Regeneron (REGN) expects adjusted SG&A costs to rise further in the remaining quarters of 2014.
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth
PR Newswire - Fri Aug 29, 8:10AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6076-100free.
Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:50PM CDT
Bristol-Myers' (BMY) Daklinza has been cleared in the EU.
